Aquestive therapeutics and haisco pharmaceutical group enter licensing and supply agreement for riluzole oral film for als treatment in china

Warren, n.j., march 03, 2022 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst) (“aquestive”), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives,  announced the execution of a license, development and supply agreement with haisco pharmaceutical group co., ltd. (szse: 002653) (“haisco”), a pharmaceutical company based in the people's republic of china (“china”), for haisco to develop and exclusively commercialize exservan™ (riluzole oral film) for the treatment of amyotrophic lateral sclerosis (“als”) in china.
AQST Ratings Summary
AQST Quant Ranking